JBIO
Jade Biosciences, Inc.- Healthcare
- Biotechnology
- $1.09B market cap
Forecast run · Sep 14, 2026Upside rank 282 of 3,136
Model Signal
ForecastQ Daily Probabilities
62.7%
24.2%
42.0%
Analyst Consensus
Recommendation2.00/5 Buy
Last price$17.89
Price target$47.83
Implied move+167.4%
Analysts4
ForecastQ Portfolios
JBIO is not in any ForecastQ portfolio today. The model scores it with every run; the names it picked are in Portfolios.
Company Profile
Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases. It develops JADE101, a monoclonal antibody to block the A PRoliferation Inducing Ligand protein, which is in phase 1 clinical trial. The company also develops JADE201 and JADE-003, which are in preclinical development stage. Jade Biosciences, Inc. has a collaboration agreement with Paragon Therapeutics, Inc. Jade Biosciences, Inc. is based in Waltham, Massachusetts.